New cases of prostate cancer are increasing faster than for any other type of major cancer, and with an increasing death rate. Early detection screening is the first step that men can take to defend themselves against this crisis. However, the US Preventive Services Task Force’s (USPSTF) 2012 screening recommendation sidelined primary care providers as the first line of defense for prostate cancer, and its updated 2018 recommendation still left significant gaps in this defense. This session will address the critical role that early detection screening must play in escalating prostate cancer cases and examine the impact of the gaps in primary care support. The impact that the USPSTF guidelines have had on reducing the over-treatment of men with low-risk disease will also be examined. The current (2025) National Comprehensive Cancer Network’s (NCCN) prostate cancer screening guidelines and the current (2018) USPSTF’s recommendation will be compared to analyze what’s needed to meet today’s needs.
Understanding the Trend of New Cases of Prostate Cancer from 2000 to 2025: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN
The Impact of the USPSTF Prostate Cancer Screening Recommendations for 2012 and 2018: J. Jacques Carter, MD, MPH, Primary Care Physician, Harvard Medical School
The Current NCCN Guidelines Compared to the USPSTF 2018 Recommendation: Bettina F. Drake, PhD, MPH, Michael F. Neidorff Professor, Division of Public Health Sciences, Washington University School of Medicine
Panel Discussion: What is Needed Today to Meet the Early Detection of Prostate Cancer Challenge?